Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PENGUIN 1
  • Sponsors Gilead Sciences

Most Recent Events

  • 04 Jun 2022 Results assessing efficacy and safety of switching from filgotinib to tofacitinib in patients with psoriatic arthritis after 6 months of follow-up from two clinical studies: PENGUIN 1 and PENGUIN 2 and presented at the 23rd Annual Congress of the European League Against Rheumatism
  • 05 Oct 2021 This trial has been completed in Poland, according to European Clinical Trials Database record. (2021-05-11)
  • 06 Jun 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top